| cyclosporine / Generic mfg. |
2020-004194-51: A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate to severe atopic dermatitis. Badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania leków - cyklosporyny i metotreksatu u dzieci i młodzieży z atopowym zapaleniem skóry o nasileniu umiarkowanym do ciężkiego. |
|
|
| Not yet recruiting | 3 | 317 | Europe | Cyclosporin, Methotrexate, Mometasone furoate, Tacrolimus, Oral solution, Ointment | Medical University of Lodz, Medical Research Agency | Atopic dermatitis Atopowe Zapalenie Skóry, Atopic dermatitis Atopowe Zapalenie Skóry, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
jRCTs031180243: JCOG0907: A Non-Randomized Validation Trial of a Therapy Incorporating Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Adult T-Cell Leukemia and Lymphoma |
|
|
| Completed | 3 | 110 | Japan | carboplatin - Generic mfg., cytarabine - Generic mfg., methotrexate - Generic mfg., prednisolone - Generic mfg., vincristine - Generic mfg., cyclophosphamide - Generic mfg., doxorubicin hydrochloride - Generic mfg., Cymerin (ranimustine) - Mitsubishi Tanabe, vindesine - Generic mfg., etoposide oral - Generic mfg., busulfan - Generic mfg., cyclosporine - Generic mfg., tacrolimus oral - Generic mfg., fludarabine oral - Generic mfg., prednisolone - Generic mfg., Lioplim (filgrastim) - Abbott, Neu-up (nartograstim) - Yakult Honsha, Granocyte (lenograstim) - Roche, Poteligeo (mogamulizumab-kpkc) - Kyowa Kirin | Saitama Medical University International Medical Center | Adult T-cell leukemia-lymphoma | | | | |
2008-003540-11: Preventie van ernstige Graft versus Host ziekte na allogene stamcel transplantatie gegeven als immuuntherapie voor patienten met een hematologische ziekte. Een gerandomiseerde fase III studie (HOVON 96 GVHD). |
|
|
| Ongoing | 3 | 500 | Europe | Ciclosporine, Myfortic, cyclophosphamide, Capsule, soft, Tablet, Powder for solution for infusion, Concentrate for solution for infusion, Myfortic 180 mg, Myfortic 360 mg | HOVON Foundation, Dutch Cancer Society, HOVON Foundation, Novartis Pharma BV, Novartis Pharma NV, Fresenius, Dutch Cancer society, Hovon Foundation, Novartis pharma BV, Novartis Pharma Belgium | Graft versus Host Disease, Graft versus Host Disease, Diseases [C] - Cancer [C04] | | | | |
2014-000699-24: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à dose intermédiaire en consolidation et le mycophénolate mofétil à la prophylaxie standard dans la prévention de la maladie du greffon contre l’hôte chez les patients allogreffés en première rémission complète : essai Backbone Inter-Group-1 (BIG-1) Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à dose intermédiaire en consolidation et le mycophénolate mofétil à la prophylaxie standard dans la prévention de la maladie du greffon contre l’hôte chez les patients allogreffés en première rémission complète : essai Backbone Inter-Group-1 (BIG-1) |
|
|
| Ongoing | 3 | 3000 | Europe | idarubicine, cytarabine, daunorubicine, ciclosporine, methotrexate, acide mycophénolique, Solution for infusion, Powder for solution for infusion, Capsule, soft, Solution for injection, Tablet, Oral solution | CHU Angers-DAMR, PHRC | Leucémie aiguë myéloïde Leucémie aiguë myéloïde, Leucémie aiguë myéloïde Leucémie aiguë myéloïde, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2005-000380-26: A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients |
|
|
| Ongoing | 3 | 168 | Europe | Certican®, RAD001, Certican®, Certican® | Novartis Farmacéutica S.A. | Renal Transplant | | | | |
2010-018353-36: BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycophenolate (either mofetil or sodium) in association with Cyclosporine in patients with acute multiple/late rejection, cardiac allograft vasculopathy, renal dysfunction after cardiac transplantation |
|
|
| Ongoing | 3 | 400 | Europe | CERTICAN, CELLCEPT, MYFORTIC, CERTICAN, CELLCEPT, MYFORTIC | AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA, GRANDA (A.O. DI RILIEVO NAZIONALE) | Paitents will be enrolled at least one year after heart transplant | | | | |
2011-000088-28: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial |
|
|
| Ongoing | 3 | 300 | Europe | Sirolimus, Mycophenolatmofetil, Cyclosporine, EU/1/01/171/007, EU/1/01/171/001, EU/1/96/005/001, EU/1/96/005/004, EU/1/96/005/005, Coated tablet, Oral liquid, Capsule, Tablet, Powder for concentrate for solution for infusion, Capsule, soft, Oral suspension, Concentrate and solvent for concentrate for solution for infusion, Rapamune, CellCept, Sandimmun | Fred Hutchinson Cancer Research Center | Graft versus host disease, Graft versus host disease is a process where donor cells may react against cells of your body causing inflammation that can involve the skin, liver and gastrointestinal system., Not possible to specify | | | | |
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
|
|
| Completed | 3 | 463 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo, Topical corticosteroid | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 11/19 | 04/23 | | |
|
NCT04979884: Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital |
|
|
| Completed | 3 | 102 | RoW | cyclosporine, interleukin-2 | Alexandria University, Science and Technology Development Fund (STDF), ,Egypt | COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis | 09/22 | 12/22 | | |
NCT05057468: Second-line Treatment of Primary Autoimmune Hemolytic Anemia |
|
|
| Recruiting | 3 | 30 | RoW | Cyclosporine, Rituximab | Assiut University | Primary Autoimmune Hemolytic Anemia | 11/22 | 11/22 | | |
NCT05149313 / 2021-002967-23: A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine |
|
|
| Completed | 3 | 331 | Europe | Lebrikizumab, Lebrikizumab-matching Placebo | Almirall, S.A. | Dermatitis, Atopic, Eczema | 01/23 | 05/24 | | |
|
NCT04743739: Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN |
|
|
| Recruiting | 3 | 126 | RoW | Rituximab, CD20 antibody, cyclosporine, CsA | Peking Union Medical College Hospital, Beijing Tongren Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, The Luhe Teaching Hospital of the Capital Medical University, The Seventh Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Xinjiang Medical University, Nanyang Nanshi Hospital of Henan University, Shanghai Fosun Pharmaceutical Development Co, Ltd. | Idiopathic Membranous Nephropathy | 03/23 | 03/25 | | |
| Recruiting | 3 | 190 | RoW | Sitagliptin + Standard Prophylaxis, Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin, Standard Prophylaxis | The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, The Second People's Hospital of Huai'an, The First People's Hospital of Changzhou, Xinqiao Hospital of Chongqing, Shenzhen People's Hospital | Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation | 05/23 | 02/24 | | |
NCT05862233: A Clinical Study of MIL62 in Primary Membranous Nephropathy |
|
|
| Recruiting | 3 | 150 | RoW | MIL62, Cyclosporine | Beijing Mabworks Biotech Co., Ltd. | Primary Membranous Nephropathy | 12/24 | 06/26 | | |
| Recruiting | 3 | 267 | US | Harmonized supportive care, Cyclosporine 5 mg/kg bid days 0-14, Etanercept 50 mg sc day 0 and day 3 | Vanderbilt University Medical Center, University of Ottawa, University of Toronto | Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | 08/27 | 08/28 | | |
TransIT, NCT05600426: A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (, BMT CTN 2202) |
|
|
| Recruiting | 3 | 234 | US | cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), ATGAM, rabbit anti-thymocyte globulin (ATG), thymoglobulin, Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST) | Boston Children's Hospital, Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network | Severe Aplastic Anemia | 12/29 | 12/29 | | |
ChiCTR1900028153: A Multi-centre Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia |
|
|
| Completed | 2/3 | 100 | | Pai-Neng-Da Capsule + Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D) ;Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D) | Jinhua people's Hospital; None, Project of Zhejiang Province TCM Science Research Fund in 2015 | Aplstic Anemia | | | | |
NCT05553496: Assessment of Rituximab Therapeutic Response Versus Conventional Treatment |
|
|
| Not yet recruiting | 2/3 | 40 | NA | Rituximab, Dexamethasone, Tacrolimus, Mycophenloatemofetil, Cyclophosphamide, Cyclosporine | Ain Shams University | Pharmacological Action | 04/23 | 10/23 | | |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 06/24 | | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Not yet recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
| Recruiting | 2/3 | 60 | | MAFU Granules + basic treatment ;cyclosporine + basic treatment | Beijing Hospital of TCM, Capital Medical University; Beijing Hospital of TCM, Capital Medical University, China association of Chinese medicine | Membranous Nephropathy | | | | |
